C Nabhan

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Gemcitabine in hematologic malignancies
    C Nabhan
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Curr Opin Oncol 13:514-21. 2001
  2. ncbi request reprint Current status of monoclonal antibody therapy for chronic lymphocytic leukemia
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University, Medical School, Robert H Lurie, Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 17:253-62; discussion 264, 267, passim. 2003
  3. ncbi request reprint Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Clin Lymphoma 2:S19-23. 2002
  4. ncbi request reprint Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma
    C Nabhan
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Leuk Lymphoma 43:2145-9. 2002
  5. ncbi request reprint Caspase activation is required for gemcitabine activity in multiple myeloma cell lines
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Mol Cancer Ther 1:1221-7. 2002
  6. ncbi request reprint 8-amino-adenosine is a potential therapeutic agent for multiple myeloma
    Nancy L Krett
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Mol Cancer Ther 3:1411-20. 2004
  7. ncbi request reprint Hereditary and acquired defects in the fibrinolytic system associated with thrombosis
    Hau C Kwaan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, 333 East Huron Street, Chicago, IL 60611, USA
    Hematol Oncol Clin North Am 17:103-14. 2003
  8. ncbi request reprint Management of acute promyelocytic leukemia
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Oncol Rep 4:381-9. 2002
  9. ncbi request reprint Acute promyelocytic leukemia: evolving therapeutic strategies
    Martin S Tallman
    Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    Blood 99:759-67. 2002
  10. ncbi request reprint In vitro assessment of nucleoside analogs in multiple myeloma
    Nancy L Krett
    Division of Hematology and Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Chemother Pharmacol 54:113-21. 2004

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Gemcitabine in hematologic malignancies
    C Nabhan
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Curr Opin Oncol 13:514-21. 2001
    ..The activity of gemcitabine in these disorders will pave the way for incorporating this agent into the early phases of therapy...
  2. ncbi request reprint Current status of monoclonal antibody therapy for chronic lymphocytic leukemia
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University, Medical School, Robert H Lurie, Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 17:253-62; discussion 264, 267, passim. 2003
    ..In this review, we discuss the clinical data on the activity of commercially available antibodies in CLL, both as monotherapy and in combination with other agents...
  3. ncbi request reprint Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Clin Lymphoma 2:S19-23. 2002
    ..This agent is currently being investigated in many clinical trials as a front-line approach in previously untreated individuals, and it is likely that it will have many more indications in the near future...
  4. ncbi request reprint Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma
    C Nabhan
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Leuk Lymphoma 43:2145-9. 2002
    ..The patient was not exposed to topoisomerase II inhibitors. Our observations suggest a relationship between 11q23 leukemia and radioimmunotherapy (RAIT) and further studies are needed...
  5. ncbi request reprint Caspase activation is required for gemcitabine activity in multiple myeloma cell lines
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Mol Cancer Ther 1:1221-7. 2002
    ..There is a suggestion that mitochondrial integrity is being affected with gemcitabine in this system. Gemcitabine acts independently of interleukin 6, suggesting potential important therapeutic implications in MM patients...
  6. ncbi request reprint 8-amino-adenosine is a potential therapeutic agent for multiple myeloma
    Nancy L Krett
    Division of Hematology Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Mol Cancer Ther 3:1411-20. 2004
    ..We have shown previously that a novel purine analogue, 8-chloro-adenosine, has significant activity for MM in preclinical studies...
  7. ncbi request reprint Hereditary and acquired defects in the fibrinolytic system associated with thrombosis
    Hau C Kwaan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, 333 East Huron Street, Chicago, IL 60611, USA
    Hematol Oncol Clin North Am 17:103-14. 2003
    ..Thus, a thorough investigation into other hereditary and acquired risk factors for thrombosis is recommended...
  8. ncbi request reprint Management of acute promyelocytic leukemia
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Oncol Rep 4:381-9. 2002
    ..Incorporation of such agents into the treatment of patients with high-risk disease may be an important future direction to pursue...
  9. ncbi request reprint Acute promyelocytic leukemia: evolving therapeutic strategies
    Martin S Tallman
    Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    Blood 99:759-67. 2002
    ..As experience with ATRA and arsenic trioxide in patients with APL accumulates, a number of important questions arise that need to be addressed...
  10. ncbi request reprint In vitro assessment of nucleoside analogs in multiple myeloma
    Nancy L Krett
    Division of Hematology and Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Cancer Chemother Pharmacol 54:113-21. 2004
    ..To identify nucleoside analogs that may be effective for multiple myeloma (MM), we tested fludarabine, clofarabine, arabinosylguanine, cytarabine, troxacitabine, and gemcitabine in MM cell lines...
  11. pmc Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
    C Nabhan
    Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Br J Cancer 107:592-7. 2012
    ..Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients...
  12. ncbi request reprint Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia
    Chadi Nabhan
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Semin Oncol 29:75-80. 2002
    ..This concept is being explored at our institution in the context of a phase I/II clinical trial. The outcome and feasibility of this combination opens the way for future combination therapies using novel biologic agents...
  13. ncbi request reprint The role of bone marrow transplantation in acute promyelocytic leukemia
    C Nabhan
    Division of Hematology-Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Bone Marrow Transplant 28:219-26. 2001
    ..A randomized prospective clinical trial, or a retrospective analysis of the available data would be useful in answering this critical question...
  14. doi request reprint Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?
    C Nabhan
    Department of Medicine, Division of Hematology and Oncology, Lutheran General Hospital, Park Ridge, IL 60068, USA
    Bone Marrow Transplant 45:1379-87. 2010
    ..We then analyze the data on HSCT in relapsed MCL and as a frontline approach propose applying the new prognostic index, MIPI (MCL International Prognostic Index), in the decision making...
  15. ncbi request reprint Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial
    A Radhakrishnan
    Department of Medicine, Division of Hematology Oncology, Advocate Lutheran General Hospital, IL 60068, USA
    J Chemother 21:439-44. 2009
    ..9 months with 49% of patients alive at 1 year. Most common toxicities were nausea, vomiting, and dehydration. This combination has notable activity in advanced non-small cell lung cancer with a favorable toxicity profile...
  16. ncbi request reprint Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old
    Simrit Parmar
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Leuk Res 28:909-19. 2004
    ..All subjects had progressive disease. There was no direct treatment-related mortality. Based on this study, we do not recommend single agent ATO as a treatment option for AML...
  17. ncbi request reprint Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
    Chadi Nabhan
    Division of Hematology and Oncology, Lutheran General Hospital Cancer Center, Park Ridge, IL, USA
    Br J Haematol 136:379-92. 2007
    ....
  18. doi request reprint Controversies in the front-line management of chronic lymphocytic leukemia
    Chadi Nabhan
    Oncology Specialists, S C, Lutheran General Hospital, Department of Medicine, Division of Hematology and Medical Oncology, Park Ridge, IL 60068, USA
    Leuk Res 32:679-88. 2008
    ..The review is intended to discuss and simplify first-line therapy selection for patients with CLL in the era of new prognostic indicators and the better understanding of disease biology...
  19. ncbi request reprint Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up
    Chadi Nabhan
    Department of Medicine, Division of Hematology Oncology, Advocate Lutheran General Hospital and Cancer Care Center, Park Ridge, IL 60078, USA
    Clin Colorectal Cancer 6:436-41. 2007
    ..We aimed to determine efficacy and tolerability of preoperative mitomycin, fluorouracil (5-FU), and leucovorin (LV) concurrent with hyperfractionated radiation therapy (RT) followed by surgery and adjuvant chemotherapy...
  20. ncbi request reprint Hodgkin's lymphoma involving the CNS
    Ewelina Morawa
    Department of Medicine, Lutheran General Hospital, Park Ridge, IL, USA
    J Clin Oncol 25:1437-8. 2007
  21. ncbi request reprint Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
    Chadi Nabhan
    S C Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
    Leuk Res 29:53-7. 2005
    ..These early results suggest that the option of single agent monoclonal antibody therapy is viable in this patient population and that additional studies are warranted with this agent either alone or in combination as initial therapy...
  22. ncbi request reprint A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Chadi Nabhan
    Oncology Specialists, S C Lutheran General Hospital Cancer Care Center, Park Ridge, Illinois 60068, USA
    Leuk Lymphoma 45:2269-73. 2004
    ..These studies are currently underway...
  23. ncbi request reprint The emerging role of alemtuzumab in chronic lymphocytic leukemia
    Chadi Nabhan
    Oncology Specialists, SC, and Division of Hematology and Oncology, Lutheran General Hospital Cancer Care Center, 1700 Luther Lane, Park Ridge, IL 60068, USA
    Clin Lymphoma Myeloma 6:115-21. 2005
    ..This review summarizes the clinical experience with alemtuzumab that eventually led to its approval. Recent novel prognostic factors and trends in CLL therapy are also reviewed...
  24. ncbi request reprint It is follicular... . so, why CHOP?
    Chadi Nabhan
    J Clin Oncol 25:915-6; author reply 916-7. 2007
  25. ncbi request reprint Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?
    Chadi Nabhan
    J Clin Oncol 24:2967-8; author reply 2968-9. 2006
  26. ncbi request reprint A simple wish...Unfulfilled
    Chadi Nabhan
    Lutheran General Hospital Cancer Institute, Park Ridge, IL 60068, USA
    J Clin Oncol 24:1217-8. 2006
  27. ncbi request reprint Chronic lymphocytic leukemia: to transplant or not to transplant... that is the question?
    Chadi Nabhan
    J Clin Oncol 23:8126-7; author reply 8127. 2005
  28. ncbi request reprint Should we transplant indolent lymphoma?
    Chadi Nabhan
    J Clin Oncol 23:6263-4; author reply 6264-6. 2005
  29. ncbi request reprint Chemotherapy for advanced prostate cancer
    Chadi Nabhan
    N Engl J Med 352:200-1; author reply 200-1. 2005
  30. ncbi request reprint Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era
    Chadi Nabhan
    Oncology Specialists, S C, Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
    Leuk Res 28:429-42. 2004
    ..These drugs are increasingly used as initial therapy in CLL. Such strategies are associated with higher remission rates than have been previously achieved and in some cases, molecular remission, suggesting an important step towards cure...